{"id":597,"date":"2018-07-13T12:46:40","date_gmt":"2018-07-13T17:46:40","guid":{"rendered":"http:\/\/blogs.uml.edu\/m2d2\/?p=597"},"modified":"2018-08-06T12:36:53","modified_gmt":"2018-08-06T17:36:53","slug":"blockchain-artificial-intelligence-and-healthcare-converge-september-13th-at-m2d2-workshop","status":"publish","type":"post","link":"https:\/\/blogs.uml.edu\/m2d2\/2018\/07\/13\/blockchain-artificial-intelligence-and-healthcare-converge-september-13th-at-m2d2-workshop\/","title":{"rendered":"Blockchain, Artificial Intelligence, and Healthcare Converge September 13th at M2D2 Workshop"},"content":{"rendered":"

\"\"<\/a>Originally the province of the financial services industry, blockchain technology is now finding its place in the life sciences and healthcare field as well. Likewise, artificial intelligence and wide-ranging health economics and outcomes research are gaining traction and demonstrating their potential for clinical and economic impact to providers, payors, and healthcare decision-makers\u2014allowing for efficient market access and a competitive edge.<\/p>\n

A half-day medical affairs workshop on Thursday, September 13th will shed light on these and other topics from the frontiers of medical technology. Hosted by UMass M2D2 in Lowell, the session is open to all healthcare professionals, entrepreneurs, startups, investors and industry experts.\u00a0Light breakfast, lunch, and ice cream will be served.<\/strong><\/em><\/p>\n

<\/p>\n

Reserve your seat here.<\/a><\/strong><\/p>\n

Meet our featured speakers:<\/strong><\/p>\n

\"\"Kate Merton
\n<\/strong>Head, JLABS @ NYC & Boston
\n<\/strong>Johnson & Johnson Innovation
\n<\/strong>During her career, Kate has been part of teams that have discovered new drugs, and has worked to develop and gain approval for blockbuster diabetes products. Kate received her undergraduate degree in Pharmacology & Toxicology from King\u2019s College London, holds a PhD in Pharmacology & Toxicology from the\u00a0University of California, Irvine Medical School and received her MBA from the Fuqua School of Business at Duke University.<\/p>\n

\"\"Ibraheem Badejo, Ph.D
\nSenior Director \u2013 New Ventures (Med Devices)
\nJohnson & Johnson Innovation Center, Boston<\/strong><\/div>\n

Ibraheem Badejo leverages his expertise in smart materials and biomaterials to support the medical device sector of Johnson & Johnson. From 2010 to 2013, Ibraheem was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by Johnson & Johnson in 2005). Ibraheem has held various positions at Bayer, North Carolina State University, and the College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.<\/p>\n

\"\"
\nKris Srinivasan, MD
\nCEO, Life Sciences, Alpha MD<\/strong><\/div>\n

As CEO of Alpha MD, a life sciences research and consulting firm, Kris is responsible for implementing the company’s product strategy and identifying and evaluating opportunities for product enhancement. He also provides risk mitigation and management strategies to clients seeking FDA or EU approval.<\/p>\n

\"\"Edward Bukstel
\nCEO, Clinical Blockchain<\/strong><\/div>\n

Edward describes Clinical Blockchain as a \u201cnot so stealthy\u201d blockchain startup that\u2019s focused on clinical information and patient\/physician messaging. His published articles explore a range of blockchain-related topics, including the interoperability of disparate blockchain systems in the healthcare ecosystem, and the vital balance between security and patients\u2019 needs for records access.<\/p>\n

\"\"Peter Johnson, MD
\nPrincipal, MedSurgPI, LLC<\/strong><\/div>\n

Peter is a co-founder of MedSurgPI, a firm that provides commercial Chief Medical Officer services for pharmaceutical, biotechnology, medical device, and related technology companies and institutions, with the aim of furthering the penetration of their technologies into clinical practice. He is also an adjunct professor of Biomedical Engineering at Duke University, and board member\/advisor to several life sciences companies and organizations.<\/p>\n

\"\"Gerald Klein, MD
\nPrincipal, MedSurgPI, LLC<\/strong><\/div>\n

Gerald L. Klein, MD\u00a0\u00a0is a\u00a0board-certified\u00a0Allergist and Immunologist, and a board certified Pediatrician.\u00a0He is an expert in Medical Affairs and Clinical Development and has published numerous scientific papers.\u00a0He was a professor of Medicine and Pediatrics (Division of Basic and Applied Immunology) at University California, Irvine. Dr. Klein was a founder and CEO of Entera Health Inc., a biotherapeutics company.\u00a0There, he created and managed both the clinical development and medical affairs programs.\u00a0He was the Chief Medical Officer of Talecris\/Grifols and he was also its VP of Medical and Clinical Affairs. During his tenure at Talecris,\u00a0Dr. Klein was instrumental in creating a comprehensive safety and pharmacovigilance plan and helping the company gain a new neurological indication.<\/p>\n

\"\"Richard Nordstrom
\nCEO, Liberate Ideas, Inc.<\/strong><\/div>\n

Richard has 30 years of life science communications experience and is recognized as an industry thought leader in health communications and patient engagement. He has led the development of countless programs around the world designed to engage patients and overcome the communication issues associated with low health literacy. He is the CEO of\u00a0Liberate Ideas, Inc. Prior to his entrepreneurial endeavors in rare disease education and literacy; Richard led McCann\u00a0Healthcare\u00a0Worldwide as its global Chairman and Chief Executive Officer. McCann was the world\u2019s largest medical communications and advertising network.<\/p>\n

\"\"Steven Schwartz
\nManaging Director in the Founders Practice at CEO Quest<\/strong><\/div>\n

Steve is recognized as an innovation leader in the fields of risk management, cybersecurity, and personal data. As a Founding Member and Vice-Chairman of the International Personal Data Trade Association, he has been on the forefront of the movement to ensure appropriate protection and use of consumer data. Recently\u00a0named \u201cNew York City\u2019s 2017 33 Under 33,\u201d Steve has personally consulted, managed and negotiated the risk management & insurance programs for worldwide, publicly-traded entities across 40 countries. A noted thought leader on the topic of risk management of cyber-related assets like personal data, he is often sought out to speak at the world\u2019s largest insurance conferences.<\/p>\n

\"\"Robert Bausmith
\nManaging Director in the CEO Practice at CEO Quest<\/strong><\/div>\n

Bob has a diverse background as a serial entrepreneur, Fortune 100 executive, managing partner, enterprise systems architect, solution architect, sales engineer product development engineer, angel investor, and advisor to dozens of CTOs, COOs, CEOs, and Boards at companies of all sizes. As the Chief Enterprise Systems Architect for UnitedHealth Group in the early 2000s, he pioneered the use of Service Oriented Architecture to design an adaptive and scalable technology ecosystem for what is today the largest healthcare services company in the world. He is a co-inventor on three US patents.<\/p>\n

<\/div>\n
<\/div>\n
<\/div>\n
See the full workshop agenda and reserve your seat.<\/a><\/strong><\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

Originally the province of the financial services industry, blockchain technology is now finding its place in the life sciences and healthcare field as well. Likewise, artificial intelligence and wide-ranging health economics and outcomes research are gaining traction and demonstrating their … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":328,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/posts\/597"}],"collection":[{"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/users\/328"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/comments?post=597"}],"version-history":[{"count":30,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/posts\/597\/revisions"}],"predecessor-version":[{"id":639,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/posts\/597\/revisions\/639"}],"wp:attachment":[{"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/media?parent=597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/categories?post=597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/tags?post=597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}